AAAAAA
Results: 26-50/63
Authors:
Gobert, A
Dekeyne, A
Millan, MJ
Citation: A. Gobert et al., The ability of WAY100,635 to potentiate the neurochemical and functional actions of fluoxetine is enhanced by co-administration of SB224,289, but notBRL15572, NEUROPHARM, 39(9), 2000, pp. 1608-1616
Authors:
Newman-Tancredi, A
Chaput, C
Touzard, M
Millan, MJ
Citation: A. Newman-tancredi et al., [S-35]-GTP gamma S autoradiography reveals alpha(2) adenoceptor-mediated G-protein activation in amygdala and lateral septum, NEUROPHARM, 39(6), 2000, pp. 1111-1113
Authors:
Dekeyne, A
Denorme, B
Monneyron, S
Millan, MJ
Citation: A. Dekeyne et al., Citalopram reduces social interaction in rats by activation of serotonin (5-HT)(2C) receptors, NEUROPHARM, 39(6), 2000, pp. 1114-1117
Authors:
Millan, MJ
Girardon, S
Monneyron, S
Dekeyne, A
Citation: Mj. Millan et al., Discriminative stimulus properties of the dopamine D-3 receptor agonists, PD128,907 and 7-OH-DPAT: a comparative characterization with novel ligands at D-3 versus D-2 receptors, NEUROPHARM, 39(4), 2000, pp. 586-598
Authors:
Cussac, D
Newman-Tancredi, A
Nicolas, JP
Boutin, JA
Millan, MJ
Citation: D. Cussac et al., Antagonist properties of the novel antipsychotic, S16924, at cloned, humanserotonin 5-HT2C receptors: a parallel phosphatidylinositol and calcium accumulation comparison with clozapine and haloperidol, N-S ARCH PH, 361(5), 2000, pp. 549-554
Authors:
Cussac, D
Newman-Tancredi, A
Sezgin, L
Millan, MJ
Citation: D. Cussac et al., [H-3]S33084: a novel, selective and potent radioligand at cloned, human dopamine D-3 receptors, N-S ARCH PH, 361(5), 2000, pp. 569-572
Authors:
Cussac, D
Newman-Tancredi, A
Quentric, Y
Millan, MJ
Citation: D. Cussac et al., An innovative method for rapid characterisation of phospholipase C activity: SB242,084 competitively antagonises 5-HT2C receptor-mediated [H-3]phosphatidylinositol depletion, N-S ARCH PH, 361(2), 2000, pp. 221-223
Authors:
Newman-Tancredi, A
Audinot, V
Moreira, C
Verriele, L
Millan, MJ
Citation: A. Newman-tancredi et al., Inverse agonism and constitutive activity as functional correlates of serotonin h5-HT1B receptor/G-protein stoichiometry, MOLEC PHARM, 58(5), 2000, pp. 1042-1049
Authors:
Millan, MJ
Citation: Mj. Millan, Improving the treatment of schizophrenia: Focus on serotonin (5-HT)(1A) receptors, J PHARM EXP, 295(3), 2000, pp. 853-861
Authors:
Millan, MJ
Dekeyne, A
Newman-Tancredi, A
Cussac, D
Audinot, V
Milligan, G
Duqueyroix, D
Girardon, S
Mullot, J
Boutin, JA
Nicolas, JP
Renouard-Try, A
Lacoste, JM
Cordi, A
Citation: Mj. Millan et al., S18616, a highly potent, spiroimidazoline agonist at alpha(2)-adrenoceptors: I. Receptor profile, antinociceptive and hypothermic actions in comparison with dexmedetomidine and clonidine, J PHARM EXP, 295(3), 2000, pp. 1192-1205
Authors:
Millan, MJ
Lejeune, F
Gobert, A
Brocco, M
Auclair, A
Bosc, C
Rivet, JM
Lacoste, JM
Cordi, A
Dekeyne, A
Citation: Mj. Millan et al., S18616, a highly potent spiroimidazoline agonist at alpha(2)-adrenoceptors: II. Influence on monoaminergic transmission, motor function, and anxiety in comparison with dexmedetomidine and clonidine, J PHARM EXP, 295(3), 2000, pp. 1206-1222
Authors:
Millan, MJ
Gobert, A
Newman-Tancredi, A
Lejeune, F
Cussac, D
Rivet, JM
Audinot, V
Dubuffet, T
Lavielle, G
Citation: Mj. Millan et al., S33084, a novel, potent, selective, and competitive antagonist at dopamineD-3-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626, J PHARM EXP, 293(3), 2000, pp. 1048-1062
Authors:
Millan, MJ
Dekeyne, A
Rivet, JM
Dubuffet, T
Lavielle, G
Brocco, M
Citation: Mj. Millan et al., S33084, a novel, potent, selective, and competitive antagonist at dopamineD-3-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626, J PHARM EXP, 293(3), 2000, pp. 1063-1073
Authors:
Millan, MJ
Gobert, A
Bervoets, K
Rivet, JM
Veiga, S
Brocco, M
Citation: Mj. Millan et al., Induction of spontaneous tail-flicks in rats by blockade of transmission at N-methyl-D-aspartate receptors: Roles of multiple monoaminergic receptorsin relation to the actions of antipsychotic agents, J PHARM EXP, 292(2), 2000, pp. 672-683
Authors:
Millan, MJ
Gobert, A
Newman-Tancredi, A
Lejeune, F
Cussac, D
Rivet, JM
Audinot, V
Adhumeau, A
Brocco, M
Nicolas, JP
Boutin, JA
Despaux, N
Peglion, JL
Citation: Mj. Millan et al., S18327 (1-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperid-1-yl]ethyl}3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1) and alpha(2)-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profile, J PHARM EXP, 292(1), 2000, pp. 38-53
Authors:
Millan, MJ
Brocco, M
Rivet, JM
Audinot, V
Newman-Tancredi, A
Maiofiss, L
Queriaux, S
Despaux, N
Peglion, JL
Dekeyne, A
Citation: Mj. Millan et al., S18327 (1-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperid-1-yl]ethyl}3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1) and alpha(2)-adrenergic receptors: II. Functional profile and a multiparametric comparison with haloperidol, clozapine,and 11 other antipsychotic agents, J PHARM EXP, 292(1), 2000, pp. 54-66
Authors:
Cussac, D
Newman-Tancredi, A
Sezgin, L
Millan, MJ
Citation: D. Cussac et al., The novel antagonist, S33084, and CR218,231 interact selectively with cloned and native, rat dopamine D-3 receptors as compared with native, rat dopamine D-2 receptors, EUR J PHARM, 394(1), 2000, pp. 47-50
Authors:
Millan, MJ
Audinot, V
Honore, P
Bervoets, K
Veiga, S
Brocco, M
Citation: Mj. Millan et al., Blockade of NMDA receptors in the nucleus accumbens elicits spontaneous tail-flicks in rats, EUR J PHARM, 388(1), 2000, pp. 37-47
Authors:
Millan, MJ
Girardon, S
Dekeyne, A
Citation: Mj. Millan et al., 5-HT2C receptors are involved in the discriminative stimulus effects of citalopram in rats, PSYCHOPHAR, 142(4), 1999, pp. 432-434
Authors:
Dubuffet, T
Newman-Tancredi, A
Cussac, D
Audinot, V
Loutz, A
Millan, MJ
Lavielle, G
Citation: T. Dubuffet et al., Novel benzopyrano[3,4-c]pyrrole derivatives as potent and selective dopamine D-3 receptor antagonists, BIOORG MED, 9(14), 1999, pp. 2059-2064
Authors:
Millan, MJ
Brocco, M
Gobert, A
Joly, F
Bervoets, K
Rivet, JM
Newman-Tancredi, A
Audinot, V
Maurel, S
Citation: Mj. Millan et al., Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: importance of nucleus accumbens 5-HT2A sites for PCP-induced locomotion in the rat, EUR J NEURO, 11(12), 1999, pp. 4419-4432
Authors:
Millan, MJ
Gobert, A
Audinot, V
Dekeyne, A
Newman-Tancredi, A
Citation: Mj. Millan et al., Inverse agonists and serotonergic transmission: From recombinant, human serotonin (5-HT)(1B) receptors to G-protein coupling and function in corticolimbic structures in vivo, NEUROPSYCH, 21(2), 1999, pp. S61-S67
Authors:
Gobert, A
Millan, MJ
Citation: A. Gobert et Mj. Millan, Modulation of dialysate levels of dopamine, noradrenaline, and serotonin (5-HT) in the frontal cortex of freely-moving rats by (-)-pindolol alone andin association with 5-HT reuptake inhibitors: Comparative roles of beta-adrenergic, 5-HT1A, and 5-HT1B receptors, NEUROPSYCH, 21(2), 1999, pp. 268-284
Authors:
Gobert, A
Rivet, JM
Cistarelli, L
Melon, C
Millan, MJ
Citation: A. Gobert et al., Buspirone modulates basal and fluoxetine-stimulated dialysate levels of dopamine, noradrenaline and serotonin in the frontal cortex of freely moving rats: Activation of serotonin(1A) receptors and blockade of alpha(2)-adrenergic receptors underlie its actions, NEUROSCIENC, 93(4), 1999, pp. 1251-1262
Authors:
Millan, MJ
Citation: Mj. Millan, The induction of pain: An integrative review, PROG NEUROB, 57(1), 1999, pp. 1-164